Synthesis, Radiochemical Characterization, and Biodistribution of a 188 Re Analogue of [ 131 I]mIBG in a Neuroblastoma Xenograft Model
Journal of Labelled Compounds and Radiopharmaceuticals · 2026-03 · 69 (3)
DOI: 10.1002/jlcr.70025 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Labelled Compounds and Radiopharmaceuticals, online erschienen am 17.03.2026. Verfasst von Navin Sakhare und 11 weiteren Autor:innen. Beteiligte Einrichtung: Radiopharmaceuticals Program, Board of Radiation and Isotope Technology, Navi Mumbai, India. Hauptthemen laut MEDLINE: Neuroblastoma, 3-Iodobenzylguanidine, Rhenium, Radioisotopes. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
[ 131 I]meta‐iodobenzylguanidine (mIBG) in variable dosage forms is widely used for the therapy of neuroendocrine tumors. Our group previously reported a 99m Tc analogue of [ 131 I]mIBG that demonstrated high specificity in vitro towards norepinephrine transporter (NET)–positive neuroblastoma cells. Considering that the 99m Tc/ 188 Re pair serves as a useful theranostic combination, we herein describe the synthesis of its 188 Re analogue and evaluate its potential for therapeutic applications. A benzylguanidine derivative functionalized at the meta position via an isonitrile moiety (“ 1 ”) was employed for 188 Re complexation following Re‐“4 + 1” chemistry. Synthesized 188 Re complex 6 was evaluated in NET‐positive SK‐N‐SH neuroblastoma cells and corresponding xenograft models. Cellular uptake studies revealed that the 188 Re complex 6 exhibited ~50% of the uptake observed for [ 125 I]mIBG. Nonetheless, it retained significant NET specificity (~60%), as confirmed by inhibition experiments using desmethylimipramine (DMI). Biodistribution studies in SK‐N‐SH xenograft‐bearing mice demonstrated tumor uptake of 4.07 ± 0.08%ID/g at 30 min ( p > 0.05), with significant retention up to 3 h (4.99 ± 0.08%ID/g). Tumor uptake was shown to be NET‐specific, as pre‐treatment with excess DMI significantly inhibited tracer accumulation in vivo. Bioevaluation of the synthesized 188 Re complex 6 confirmed its affinity for NETs; however, limited in vivo stability restricted its suitability for therapeutic application.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Radiopharmaceuticals Program, Board of Radiation and Isotope Technology, Navi Mumbai, India.
- Department of Chemistry, Mangalore University, Mangalagangothri, Karnataka, India.
- Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Trombay, Mumbai, India.
- Advanced Centre for Treatment, Research & Education in Cancer, Tata Memorial Centre, Navi Mumbai, India.
ORCID-Profile: Madhava B Mallia
Zitieren
APA
Sakhare, N., Kumar, D., Das, S., Mitra, A., Mirapurkar, S., Rani, G., Sheela, M., Chirayil, V., Mohanty, B., Mathur, A., Mallia, M. B., & Chaudhari, P. (2026). Synthesis, Radiochemical Characterization, and Biodistribution of a 188 Re Analogue of [ 131 I]mIBG in a Neuroblastoma Xenograft Model. Journal of Labelled Compounds and Radiopharmaceuticals, 69(3). https://doi.org/10.1002/jlcr.70025
Vancouver
Sakhare N, Kumar D, Das S, Mitra A, Mirapurkar S, Rani G, et al. Synthesis, Radiochemical Characterization, and Biodistribution of a 188 Re Analogue of [ 131 I]mIBG in a Neuroblastoma Xenograft Model. Journal of Labelled Compounds and Radiopharmaceuticals. 2026;69(3). doi:10.1002/jlcr.70025
BibTeX
@article{Sakhare2026,
author = {Sakhare, Navin and Kumar, Dheeraj and Das, Soumen and Mitra, Arpit and Mirapurkar, Shubhangi and Rani, G and Sheela, M and Chirayil, Viju and Mohanty, Bhabani and Mathur, Anupam and Mallia, Madhava B and Chaudhari, Pradip},
title = {Synthesis, Radiochemical Characterization, and Biodistribution of a 188 Re Analogue of [ 131 I]mIBG in a Neuroblastoma Xenograft Model},
journal = {Journal of Labelled Compounds and Radiopharmaceuticals},
year = {2026},
volume = {69},
number = {3},
doi = {10.1002/jlcr.70025}
}
EUVIMED